Validity of the Patient-Reported Outcome Measurement Information System (PROMIS) Sexual Interest and Satisfaction Measures in Men Following Radical Prostatectomy

Abstract

PURPOSE Patient-reported outcomes after radical prostatectomy have focused on erectile function. To date, no studies have validated the Patient-Reported Outcome Measurement Information System (PROMIS) Sexual Interest and Satisfaction single item measures in patients with prostate cancer, nor have studies examined how these measures relate to erectile function. In addition, data are lacking with regard to the clinical responsiveness of these measures to treatment. We sought to validate and examine the clinical utility of these measures in men after radical prostatectomy. PATIENTS AND METHODS We identified men who underwent a robotic radical prostatectomy from May 2014 to January 2016 in the Michigan Urological Surgery Improvement Collaborative. A single item from the PROMIS Global Satisfaction With Sex Life subdomain and a single item from the PROMIS Interest in Sexual Activity subdomain were administered. Erectile function was also assessed. Differences between baseline and 24-month T-scores for both PROMIS interest and satisfaction were examined. Multilevel models were constructed to examine change over time. RESULTS A total of 1,604 patients were included in the analysis. Convergent and discriminant validity of the PROMIS measures was supported. The mean PROMIS interest T-score decreased significantly from baseline to 3 months ( P = .001) and significantly increased from 3 months to 24 months in this cohort, with 24-month scores exceeding baseline scores ( P < .001). The mean PROMIS satisfaction T-score declined from baseline to 3 months and increased from 3 months to 24 months ( P < .002). CONCLUSION PROMIS Global Satisfaction With Sex Life and Interest in Sexual Activity single-item measures are fundamental measures in prostate cancer survivorship. Patients are interested in sex despite functional losses and can salvage satisfaction, thereby giving insight into attainable patient-centered survivorship goals for sexual recovery after radical prostatectomy.

Time pressure predicts decisional regret in men with localized prostate cancer: data from a longitudinal multicenter study

“…Sexual satisfaction may be more modifiable than erectile dysfunction and could thus be a starting point for interventions that aim at reducing regret. Our findings align with those of other studies [27,28] highlighting the importance of satisfaction with sexual life as a patientcentered outcome for quality of life in cancer survivors. In future, patient-reported experience measures (PREMs), like satisfaction with sexual life, will become increasingly important.…”

“…However, since treatment groups did not differ at baseline, our findings show that a substantial proportion of the deterioration in erectile functioning is attributable to local treatment. Satisfaction with sexual life, which captures psychological aspects of sexuality [27], is an important predictor for decisional regret. Sexual satisfaction may be more modifiable than erectile dysfunction and could thus be a starting point for interventions that aim at reducing regret.…”

Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives

“…LAG3 is an alternative inhibitory receptor target showing promising activity [ 192 ]; CD137 is a member of the tumor necrosis factor receptor family increasing antitumor response by altering the tumor microenvironment [ 193 ]. The Adult Brain Consortium (ABTC) 1501 trial is a phase I multicenter, multi-arm dose-finding study of anti-LAG (BMS-986016) or anti-CD137 (BMS-663513) alone or in combination with anti-PD1 treatment in patients at first GBM recurrence showing a manageable toxicity profile [ 191 ]. Epacadostat is an inhibitor of indoleamine 2,3-dioxygenase-1 (IDO1) that showed antitumor activity in several cancer models, especially when associated with other immunotherapy agents [ 194 ].…”

Advances in Immunotherapy for Adult Glioblastoma

“…4-1BB is a co-stimulatory receptor expressed by T cells upon activation, which augments activation signaling. The anti-4-1BB group had a promising median survival of 14 months [ 52 ]; however, while preclinical investigations support this therapy [ 63 , 64 ], further trials with anti-4-1BB antibodies are required.…”